"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA approves isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone for adults with multiple myeloma

FDA approves isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone for adults with multiple myeloma

03 Mar 2020 9:27 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved isatuximab-irfc (SARCLISA, sanofi-aventis U.S. LLC) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software